23:42 , Mar 14, 2019 |  BC Week In Review  |  Clinical News

CStone to start Phase I of HDAC6 inhibitor

CStone said China’s National Medical Products Administration (NMPA) approved an IND for a dose-escalation Phase I trial of CS3003 to treat advanced solid tumors and relapsed or refractory multiple myeloma. The trial of the selective...
18:49 , Nov 13, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Leukemia; multiple myeloma (MM) Cell studies identified a dual HDAC6/proteasome inhibitor that could help treat leukemia and MM. A chemical reaction coupling a N-hydroxybenzamide-based HDAC inhibitor to a tris(oxo-4-phenylbutan-2-ylamino)-based proteasome inhibitor yielded a compound...
04:47 , Nov 9, 2018 |  BC Innovations  |  Tools & Techniques

HitGen’s DNA for small molecules

With more than 60 partnerships under its belt, HitGen Ltd. has become a major gateway for companies to access DNA-encoded library technology -- a high efficiency form of combinatorial chemistry that upstages high throughput screening....
17:36 , Sep 26, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Leukodystrophy Cell culture, worm and mouse studies suggest inhibiting HDAC6 and other HDACs could help treat Cockayne syndrome, a leukodystrophy caused by ERCC6 mutations that is associated with defects in autophagy, neurogenesis and neuronal...
23:50 , Aug 8, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Non-small cell lung cancer (NSCLC) In vitro , cell culture and mouse studies identified a piperazine-based dual MDM2/HDAC6 inhibitor that could help treat NSCLC. Chemical synthesis and in vitro testing of conjugates consisting of...
21:38 , Jul 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer; infectious disease

INDICATION: Acute myelogenous leukemia (AML); Candida In vitro , cell culture and mouse studies identified an aminopyrimidine-based dual JAK-2/HDAC6 inhibitor that could help treat AML and Candida albicans infection. Chemical synthesis of aminopyrimidine analogs linked...
22:25 , Apr 13, 2018 |  BioCentury  |  Emerging Company Profile

Reversing Neuropathy

Regenacy Pharmaceuticals LLC is developing the selective histone deacetylase 6 inhibitor ricolinostat as the first disease-modifying therapy for chemotherapy-induced peripheral neuropathy and diabetic neuropathy. Regenacy was spun out of Acetylon Pharmaceuticals Inc. during its 2016...
22:50 , Apr 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Arthritis In vitro and mouse studies identified a tetrahydrocarboline-based HDAC6 inhibitor that could help treat arthritis. Chemical synthesis and in vitro activity assays of tetrahydrocarboline analogs yielded a compound that inhibited HDAC6 with a...
05:42 , Jan 27, 2018 |  BioCentury  |  Strategy

Jump-starting growth

Celgene Corp.’s two deals this month -- including its largest ever acquisition, of Juno Therapeutics Inc. -- will help fill in the holes left by late-stage failures and commercial disappointments of candidates that were intended...
20:06 , Oct 24, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Amyotrophic lateral sclerosis (ALS) Cell culture studies suggest inhibiting HDAC6 could help treat ALS. In ALS patient-derived motor neurons, inhibition of HDAC6 with two tool compounds or antisense oligonucleotide (ASO)-mediated knockdown decreased axon transport...